Skip to main content

Table 1 Patient characteristics and clinical outcomes

From: Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma

Patient Sex Age Stage Site of metastasis Previous therapies (drug) Enrolled Vaccine treatment OR TTP (months) Overall survival (months)
1 F 71 IIIC Skin recurrence None Yes Complete SD 7 34
2 F 47 IV Lung, lymphonodal 2 (DTIC, Vemurafenib) Yes 2 injections PD 2 2
3 M 73 IV Skin lymphnodal, liver 3 (DTIC, Vemurafenib, Ipilimumab) Yes Complete SD 26 31
4 M 38 IV Lymphonodal, lung 1(Vemurafenib) Yes 2 injections PD 2 5
5 M 66 IV Lung, lymphonodal 3 (DTIC-IL2, BOLD, Ipilimumab) Yes Complete SD 5 9
6 F 68 IV Skin, lung, lymphonodal 2 (DTIC, Ipilimumab Yes No injection NA NA NA
7 F 63 IV Adrenal, lymphonodal none No
8 M 69 IV Brain, lymphonodal, lung, bone 3(Fotemustine, Ipilimumab, DTIC) No
9 F 51 IV Brain, lung, lymphonodal, spleen 5 (DTIC, Fotemustine, Paclitaxel, Ipilimumab, Dabrafenib No
10 M 66 IV Lung, lymphonodal, spleen 4 (DTIC+ Bevacizumab, Fotemustine, CDDP + Paclitaxel, Ipilimumab) No